Retina
Patient-centered Approaches to Reduce Treatment Burden and Optimize Anatomical and Visual Outcomes in nAMD and DME
Supported by an educational grant from Genentech, a member of the Roche Group.
Diabetic retinopathy eye drop trial fails to meet primary efficacy endpoint
OcuTerra Therapeutics is evaluating strategic alternatives after the phase 2 DR:EAM trial failed to meet its primary efficacy endpoint, according to a press release.
Retinal Disease Digest: Opportunities for Optometrists - Focus on RVO
This activity is supported by independent medical education grants from Apellis Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.
VIDEO: Delivery options for wet AMD gene therapy under investigation
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Lejla Vajzovic, MD, FASRS, discusses developments in gene therapy for wet age-related macular degeneration.
In Case You Missed...New Medical Retina Treatments: Cutting-Edge Insights
This activity is supported by independent medical education grants from Alimera Sciences, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and REGENXBIO Inc.
VIDEO: Real-world data show durability of Xipere in uveitic macular edema
In this Healio Video Perspective from the Macula Society meeting, Michael A. Singer, MD, presents real-world data investigating Xipere for the treatment of uveitic macular edema.
Opthea appoints Arshad M. Khanani as chief medical advisor
Arshad M. Khanani, MD, MA, FASRS, a renowned retina specialist and clinical researcher, has been appointed as chief medical advisor of Opthea Limited, according to a press release.
VIDEO: Vitreoretinal tools can help manage anterior segment complications
TAMPA, Fla. — In this Healio Video Perspective from Telling It Like It Is, Maria H. Berrocal, MD, shares posterior segment pearls to manage complications of anterior segment surgeries.
VIDEO: Analysis compares phase 3 data of geographic atrophy treatments
In this Healio Video Perspective from the Macula Society meeting, Dilsher Dhoot, MD, discusses data from three phase 3 trials involving pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.
Early safety, efficacy results positive for Restoret in DME, wet AMD
Restoret showed promising safety and efficacy results at 12 weeks in patients with treatment-naive diabetic macular edema and treatment-naive neovascular age-related macular degeneration, according to a press release from EyeBio.